Tech Talk: Biofabrication Speaker



Name: Andras Forgacs

Title: Co-founder and Chief Executive

Company:  Modern Meadow

Andras Forgacs, an entrepreneur and venture investor in technology and life science, is the co-founder and chief executive of Modern Meadow, which launched in 2011. Previously, he had also co-founded Organovo, a leader in tissue engineering which pioneered the use of 3D bio-printing to create human tissue for a range of medical applications. Organovo’s bio-printer was named one of the top inventions of 2010 by TIME and the company was recognized by MIT Technology Review on its TR50 list of most innovative companies for 2012. Andras also served as managing director with Richmond Global, an international technology-focused venture fund. Previously, Andras was a consultant in the New York office of McKinsey & Company, focused on biopharma and private equity. Earlier, he was a founding member of Citigroup’s corporate and investment banking e-commerce group where he led a team that developed award winning financial technology products and advised large cap corporate clients on a range of corporate finance challenges. He is also co-founder and chairman emeritus of the international non-profit Resolution Project. Andras is a Kauffman Fellow with the Center for Venture Education and a term member with the Council on Foreign Relations. He holds an MBA from the Wharton School of Business and a Bachelor of Arts with honors from Harvard University.


Name: Yiannis Monovoukas

Title: former Chairman, President and CEO

Company:  TEI Biosciences Inc & TEI Medical Inc

Yiannis Monovoukas, Ph.D., MBA, is the former Chairman, President and CEO, and major shareholder of TEI Biosciences Inc. and TEI Medical Inc., two regenerative medicine companies based on technology generated at MIT focusing on the repair, reinforcement, and regeneration of soft tissues.  Both companies were sold to Integra LifeSciences in 2015. Dr. Monovoukas is also the Founder, President and CEO of Helios Cardiovascular and Helios Biomedical, and the co-Founder, President and CEO of AuraGen Aesthetics and Quantum Medical Analytics.

Prior to joining TEI, he was President and CEO of Thermo Fibergen, a Thermo Electron (now Thermo Fisher Scientific) spin out, which he grew from an R&D concept to a profitable public company.

Dr. Monovoukas holds a BS degree from Columbia University and MS and Ph.D. degrees from Stanford University, all in chemical engineering, as well as an MBA from the Harvard Business School.

Dr. Monovoukas was winner of the prestigious Ernst & Young Entrepreneur Of The Year® 2011 Award for New England in Life Sciences, and was a 2011 Life Sciences US Finalist.  The program recognizes global entrepreneurs who demonstrate excellence and extraordinary success.  He also served on a panel of judges for the 2012, 2013 and 2014 E&Y Entrepreneur of the Year® New England Awards Program, and on the 2015 and 2016 US national judging panel for life sciences.  TEI was also winner of the SBANE 2011 New England Innovation Award.

Since 2010, Dr. Monovoukas has been serving on the Board of Directors of Owlstone, a leading-edge nanotechnology chemical sensing company span out of the University of Cambridge, England, focusing on the early detection of cancer and inflammatory diseases via highly selective identification of biomarkers in breath and bodily fluids.  From 2011 to 2014, he served as a Mentor for the Columbia Engineering Entrepreneurship Program, and as of 2015 he is serving as a member of the Board of Overseers of the Boston Museum of Science.  Dr. Monovoukas was recently elected to serve on the Board of Directors of InterAx Biotech AG, a Swiss biopharmaceutical company focusing on the discovery of novel and safer GPCR drugs.